Market revenue in 2023 | USD 4,064.2 million |
Market revenue in 2030 | USD 7,228.6 million |
Growth rate | 8.6% (CAGR from 2023 to 2030) |
Largest segment | Formulation development |
Fastest growing segment | Formulation Development |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Preformulation, Formulation Development |
Key market players worldwide | SGS, Intertek Group PLC, Recipharm, Lonza Group Ltd, Charles River Laboratories International Inc, Eurofins Scientific SE, Element Solutions Inc, Labcorp Holdings Inc, Thermo Fisher Scientific Inc, Catalent Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to formulation development outsourcing market will help companies and investors design strategic landscapes.
Formulation development was the largest segment with a revenue share of 76.81% in 2023. Horizon Databook has segmented the China formulation development outsourcing market based on preformulation, formulation development covering the revenue growth of each sub-segment from 2018 to 2030.
With several fast-expanding biotech firms, China is one of the largest markets for medicines and biotechnology in the world. In China, there were more than 1,000 biotech enterprises as of 2021, with an emphasis on innovation and R&D operations.
The country is also a major player in the vaccine industry and is expected to witness significant growth in the coming years. China emerged as a leading hub for clinical research & development, with a growing number of registered clinical trials and sites.
As of 2022, the country accounted for 27.7% of the global clinical trial activity. This trend is indicative of the country's commitment to advancing its healthcare industry through innovation and research. China's commitment to advancing its healthcare industry through innovation and research presents opportunities for businesses planning to outsource formulation development.
Horizon Databook provides a detailed overview of country-level data and insights on the China formulation development outsourcing market , including forecasts for subscribers. This country databook contains high-level insights into China formulation development outsourcing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account